A Study of APO866 for the Treatment of Cutaneous T-cell Lymphoma
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
This phase II study is designed to determine the efficacy and safety of APO866 for the
treatment of patients with advanced forms of cutaneous T-cell lymphoma (CTCL). APO866 has
shown to induce growth inhibition in cultures of human CTCL cells as well as in animal models
with subcutaneously implanted human CTCL tumors. APO866 was considered to be safe and
well-tolerated in a phase I study that treated 24 patients with advanced cancer. APO866 is
administered by intravenous infusion continuously for 96 hours and that is repeated every 4
weeks. Patients will receive 3 cycles of treatment and the primary efficacy endpoint will be
assessed at Week 16. patients will be followed up for 12 months